A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)

Inclusion Criteria: \- Women with an indication for COS prior to in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) who meet the criteria as mentioned in the current Korean ELONVA local label Exclusion Criteria: * Hypersensitivity to the active substance or to any of the excipients * Tumors of the ovary, breast, uterus, pituitary or hypothalamus * Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause. * Primary ovarian failure * Ovarian cysts or enlarged ovaries * A history of OHSS * A previous COS cycle that resulted in more than 30 follicles ≥ 11 mm measured by ultrasound examination * Basal antral follicle count \> 20 * Fibroid tumors of the uterus incompatible with pregnancy * Malformations of the reproductive organs incompatible with pregnancy * Pregnancy * Polycystic ovarian syndrome